Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy
repeatedly for 20 years. In 2012, he underwent hepatic right lobectomy for recurrence of …

Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced
hepatocellular carcinoma (HCC). Herein, we report the efficacy of sorafenib for extrahepatic …

There are only 13 cases of complete remission after sorafenib use in advanced
hepatocellular carcinoma (HCC) worldwide. We herein report a rarer case in which the …

Case 1 involved a 63-year-old woman who had multiple hepatocellular carcinomas (HCC)
associated with hepatitis C virus infection. She was treated with hepatic arterial infusion …

A 50-year-old man presented to our hospital with the chief complaint of right hypochondriac
pain and a palpable tumor. Advanced hepatocellular carcinoma (HCC) and chronic hepatitis …

Discussion We have reported details of a case of sustained complete regression of HCC
after short-term sorafenib therapy for four weeks. Complete remission of advanced HCC as a …

Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and
curative treatment remains difficult because the majority of cases are diagnosed in the …

Partial hepatectomy is still the treatment of choice aiming at a cure for patients with
hepatocellular carcinoma (HCC), provided that the patient can tolerate the treatment. For …

Sorafenib is an oral multi-targeted tyrosine kinase inhibitor used in cases of unresectable
advanced HCC that significantly improves progression-free and overall survival. Complete …

A 69-year-old woman who had a history of chronic hepatitis C, autoimmune hemolytic
anemia and myelodysplastic syndrome was treated with sorafenib at a daily dose of 400 mg …